← Leaderboards
Ryan Pawell
Indee, Inc
$2,605,206
Attributed
$2,605,206
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.3M · FY2022–23$2.5M$1.9M$1.3M$625K$0
'22
'23
Funding mix
By agency
NIH$2,605,206 · 3
By mechanism
N44$1,999,646 · 1
R43$605,560 · 2
Top collaborators
No co-investigators on record.
Others in their field
Other Rising Stars on “Performance”
- Katherine M Thibault · Battelle Memorial Institute$134,148,552
- Mari Ostendorf · University Of Washington$51,931,230
- Richard Smith · Medical Device Innovation Consortium$41,401,350
- Christina Millin · Rho Federal Systems Division, Inc.$31,828,916
- Gary Mays · Axle Informatics, Llc$30,746,223
- Michael Difilippantonio · Leidos Biomedical Research, Inc.$22,364,766
Research focus
PerformanceT-LymphocyteCellsChimeric Antigen Receptor T CellsMicrofluidicsGenesTechnologyCell TherapyCell PhysiologyImmuneEngineeringEngineered T CellsGeneticGoldInstrumentDevicesBaseDoseComplexConsumptionDesignCell SurvivalCd3 AntigensCellular Engineering
Grant awards (3)
High efficiency microfluidic device for large scale engineered cell therapy manufacturing$295,924
R43 · FY2023 · GM · contact PI
TOPIC 397 - MICROFLUIDIC VORTEX SHEDDING: A LOW-COST, HIGH EFFICIENCY METHOD FOR GENETIC MODIFICATION TO SUPPORT CELL ENGINEERING FOR CELL-BASED IMMUNOTHERAPIES$1,999,646
N44 · FY2022 · CA · contact PI
Rapid, single-step precision engineering and pre-clinical evaluation of chimeric antigen receptor Regulatory T cells for Type 1 diabetes$309,636
R43 · FY2022 · DK · contact PI